Authors
Robert, CSchachter, J
Long, G
Arance, A
Grob, J
Mortier, L
Daud, A
Carlino, M
McNeil, C
Lotem, M
Larkin, J
Lorigan, Paul C
Neyns, B
Blank, C
Hamid, O
Mateus, C
Shapira-Frommer, R
Kosh, M
Zhou, H
Ibrahim, N
Ebbinghaus, S
Ribas, A
Affiliation
Univ Paris Sud, F-94805 Villejuif, France.Issue Date
2015-06-25
Metadata
Show full item recordAbstract
The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma.Citation
Pembrolizumab versus Ipilimumab in Advanced Melanoma. 2015, 372 (26):2521-32 N. Engl J MedJournal
The New England Journal of MedicineDOI
10.1056/NEJMoa1503093PubMed ID
25891173Type
ArticleLanguage
enISSN
1533-4406ae974a485f413a2113503eed53cd6c53
10.1056/NEJMoa1503093